Prostate-specific antigen velocity and prostate cancer gleason grade and stage

53Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

BACKGROUND. Increased preoperative prostate-specific antigen (PSA) velocity (PSAV) has been associated with increased prostate cancer mortality and higher Gleason scores. The authors evaluated the relation between PSAV, biopsy Gleason score, and pathologic stage in men who were enrolled in a prostate cancer screening trial. METHODS. Data were analyzed from 1441 men who were enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who received ≥2 PSA screens and were diagnosed with prostate cancer within 1 year of the last screen. PSAV was estimated by using all screening PSA values within 6 years prediagnosis. RESULTS. Both PSA and PSAV were related to biopsy Gleason score. The multivariable odds ratios (OR), controlling for PSA and demographics, for having a Gleason score of 7 to 10 were 1.3 (95% confidence interval [95% CI], 0.9-1.9), 2.2 (95% CI, 1.5-3.3), and 2.3 (95% CI, 1.4-3.9) for men with PSAV values from 0.5 to 1 ng/mL per year, from 1 to 2 ng/mL per year, and >2 ng/mL per year, respectively, compared with men who had PSAV values <0.5 ng/mL per year. The median PSAV was 0.60 ng/mL per year for men with Gleason scores from 2 to 6 versus 0.84 ng/mL per year for men with Gleason scores from 7 to 10 (P < .0001). Among 658 men who underwent prostatectomy, both PSA and PSAV were associated with advanced pathologic stage in univariate analyses; however, when the analysis controlled for clinical stage and biopsy Gleason score, the associations of PSA and PSAV were no longer statistically significant. CONCLUSIONS. PSAV and PSA levels were associated independently with biopsy Gleason score. Among men who underwent prostatectomy, PSAV and PSA were not predictive of advanced pathologic stage when the analysis was controlled for biopsy Gleason score and clinical stage. It cannot be determined yet whether PSAV is predictive of long-term prostate cancer outcome in this cohort.

References Powered by Scopus

A method of comparing the areas under receiver operating characteristic curves derived from the same cases

6334Citations
N/AReaders
Get full text

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

864Citations
N/AReaders
Get full text

Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial

794Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring

723Citations
N/AReaders
Get full text

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era

379Citations
N/AReaders
Get full text

Tumor markers in prostate cancer I: Blood-based markers

152Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Pinsky, P. F., Andriole, G., Crawford, E. D., Chia, D., Kramer, B. S., Grubb, R., … Gohagan, J. K. (2007). Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer, 109(8), 1689–1695. https://doi.org/10.1002/cncr.22558

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

60%

Researcher 7

28%

Professor / Associate Prof. 3

12%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

52%

Agricultural and Biological Sciences 5

20%

Engineering 4

16%

Chemistry 3

12%

Save time finding and organizing research with Mendeley

Sign up for free